NCT05983107 is a Phase 2 clinical trial of Everolimus in HR+/HER2- Advanced Breast Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Who is sponsoring NCT05983107?

NCT05983107 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

What drugs are being tested in NCT05983107?

Interventions in NCT05983107: Everolimus, Chidamide, Endocrine therapy, Ovarian function suppression(OFS).

What condition does NCT05983107 study?

NCT05983107 studies HR+/HER2- Advanced Breast Cancer, Targeted Therapy.

Is NCT05983107 still recruiting?

NCT05983107 is currently recruiting now. Last updated 9 August 2023.

Last reviewed 2023-08-09 · How we verify

NCT05983107

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Recruiting now Phase 2 Last updated 9 August 2023

What this trial tests

Phase 2 trial testing Everolimus in HR+/HER2- Advanced Breast Cancer in 102 participants. Currently enrolling.

Timeline

20 July 2023

Primary endpoint
15 July 2026

15 July 2027

Quick facts

Lead sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	102
Start date	20 July 2023
Primary completion	15 July 2026
Estimated completion	15 July 2027
Sites	1 location across China

Drugs / interventions tested

Everolimus (everolimus) — full drug profile →
Chidamide — full drug profile →
Endocrine therapy (endocrine-therapy) — full drug profile →
Ovarian function suppression(OFS) — full drug profile →

Conditions studied

HR+/HER2- Advanced Breast Cancer — all drugs for HR+/HER2- Advanced Breast Cancer →
Targeted Therapy — all drugs for Targeted Therapy →

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Who can join

Adults 18 to 75, female only, with HR+/HER2- Advanced Breast Cancer or Targeted Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients and to explore the efficacy and safety of Everolimus combined with endocrine therapy in patients with PI3KCA Mutant HR+/HER2- advanced breast cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.
Mehta D, Rajput K, Jain D, Bajaj A, et al · · 2024 · cited 17× · PMID 39698262 · DOI 10.1021/acsptsci.4c00530
Histone acetylation modulators in breast cancer.
Yuan X, Rosen JM. · · 2025 · cited 4× · PMID 40165290 · DOI 10.1186/s13058-025-02006-9
Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress.
Varun D, Haque M, Jackson-Oxley J, Thompson R, et al · · 2025 · cited 1× · PMID 40805121 · DOI 10.3390/cancers17152418

Verify or expand the search:

Other trials of Everolimus

Trials testing the same drug.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07318324 — Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer · Phase 1 · not yet recruiting
NCT07477548 — A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies · Phase 2 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting

Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
NCT07537049 — BR101 in Patients With Relapsed/Refractory Multiple Myeloma · Phase 1 · not yet recruiting
NCT07187154 — The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy · NA · not yet recruiting
NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
NCT07507058 — Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05983107 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Last refreshed: 9 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05983107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing